Bristol-Myers Squibb Co (BMY)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$59.55
Buy
$59.60
$-1.50 (-2.45%)
Prices updated at 03 Apr 2026, 00:59 EDT
| Prices minimum 15 mins delay
Prices in USD
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Dr. Christopher S. Boerner, PhD
CEO
Dr. Christopher S. Boerner, PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
32,500
Head office
Route 206 and Province Line Road
New Jersey
United States
08543
Key personnel
Owner name | Salary |
|---|---|
Mr. Derica W. Rice Independent Director | 0.15m |
Mr. Michael R. McMullen Independent Director | 0.13m |
Ms. Phyllis R. Yale Independent Director | 0.14m |
Ms. Paula A. Price Independent Director | - |
Mr. Peter J. Arduini Independent Director | 0.14m |
Ms. Sandra Leung Executive Vice President and General Counsel | - |
Mr. David V. Elkins Executive Vice President and Chief Financial Officer | 1.14m |
Dr. Christopher S. Boerner, PhD Chairman of the Board and Chief Executive Officer | 1.59m |
Dr. Julia A. Haller, M.D. Independent Director | 0.15m |
Mr. Theodore R. Samuels Lead Independent Director | 0.20m |
Dr. Karen H. Vousden, PhD Independent Director | 0.14m |
Mr. Benjamin J. Hickey, M.B.A. President, RayzeBio Organization | - |
Dr. Robert M. Plenge, M.D.,PhD Executive Vice President, Chief Research Officer and Head of Research | - |
Dr. Manuel Hidalgo Medina, M.D.,PhD Independent Director | 0.14m |
Mr. Gregory Scott Meyers Executive Vice President, Chief Digital Officer and Chief Technology Officer | 1.07m |
Ms. Karin Shanahan Executive Vice President, Chief Supply Chain and Operations | - |
Dr. Deepak L. Bhatt, M.B.A.,M.D.,M.P.H. Independent Director | 0.14m |
Mr. Adam Lenkowsky Executive Vice President and Chief Commercialization Officer | 1.13m |
Ms. Cari Gallman Executive Vice President, General Counsel and Chief Policy Officer | - |
Ms. Lynelle Hoch President, Cell Therapy Organization | - |
Ms. Amanda Ahn Poole Executive Vice President and Chief People Officer | - |
Mr. Phil Holzer Senior Vice President, Principal Accounting Officer and Controller | - |
Mr. Hiroshi Chris Shibutani, M.D. Executive Vice President and Chief Strategy Officer | - |
Dr. Cristian Massacesi, M.D. Executive Vice President, Chief Medical Officer and Head of Development | 0.39m |
Ms. Wendy Short Bartie Executive Vice President, Corporate Affairs | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard Group Inc | 198,727,768 |
| BlackRock Inc | 175,515,165 |
| JPMorgan Chase & Co | 172,361,328 |
| State Street Corp | 96,595,232 |
| Vanguard | 76,164,495 |
Director dealings
Date | Action |
|---|---|
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 03 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 01 Nov 2025 | - |
| 02 Oct 2025 | - |
| 02 Oct 2025 | - |
| 02 Oct 2025 | - |
| 30 Sep 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
